Quoin Pharmaceuticals Ltd. (QNRX): Cash & Equivalents
$3.82M
As of 2025-12-31
$3.85M
As of 2026-06-30
+10.1%
3-year compound annual growth
+63.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.82M | +5.4% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $3.62M | +50.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $2.40M | -16.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $2.86M | -61.8% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $7.48M | n/m | 2023-03-15, Balance as of period end |
| 2020-12-31 | $323.8K | n/a | 2022-04-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $3.82M | +5.4% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $3.83M | +99.3% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $681.5K | +174.4% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $19.53M | +85.1% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $17.72M | +17.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $21.03M | +290.8% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $1.77M | -17.7% |
Compare QNRX, NXTS, EVFM, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗